Alnylam Pharmaceuticals (ALNY) Change in Receivables (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Change in Receivables for 18 consecutive years, with $31.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Receivables fell 76.92% year-over-year to $31.6 million; the trailing twelve-month figure through Jun 2026 stood at $357.6 million (up 48.43% YoY), and the FY2025 full-year result was $360.0 million, up 315.9% from the prior year.
• Change in Receivables slipped to $31.6 million in Q2 2026 per ALNY's latest filing, from $110.4 million in the prior quarter.
• Across five years, Change in Receivables topped out at $399.9 million in Q3 2025 and bottomed at -$184.2 million in Q4 2025.
• Historically, Change in Receivables has averaged $40.1 million across 5 years, with a median of $19.5 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Change in Receivables sank 470.68% in 2022, then surged 1913.17% in 2025.
• Over 5 years, Change in Receivables stood at $53.3 million in 2022, then plunged by 107.26% to -$3.9 million in 2023, then soared by 1638.07% to $59.5 million in 2024, then slumped by 409.62% to -$184.2 million in 2025, then surged by 117.15% to $31.6 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered $31.6 million, $110.4 million, and -$184.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.